Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 studyJoshua J. Solomon, Marilyn K. Glassberg, Sonye K. Danoff et al.|The Lancet Respiratory Medicine|2022Cited by 211
2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic DiseasesSindhu R. Johnson, Jake G. Natalini, Rohit Aggarwal et al.|Arthritis & Rheumatology|2024Cited by 162
2023 American College of Rheumatology (<scp>ACR</scp>)/American College of Chest Physicians (<scp>CHEST</scp>) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic DiseasesSindhu R. Johnson, Jake G. Natalini, Elana J. Bernstein et al.|Arthritis & Rheumatology|2024Cited by 122
Effect of Antimicrobial Therapy on Respiratory Hospitalization or Death in Adults With Idiopathic Pulmonary FibrosisFernando J. Martínez, Timothy Albertson, Eric Yow et al.|JAMA|2021Cited by 78
Combining Pirfenidone With Mycophenolate Mofetil for Systemic Sclerosis–Related Interstitial Lung Disease (Scleroderma Lung Study <scp>III</scp> ): An Investigator‐Initiated, Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Phase 2 TrialDinesh Khanna, Cathie Spino, Donald P. Tashkin et al.|ACR Open Rheumatology|2025Cited by 3